VivoSeq
Oncology

Hepatocellular Cancer

4

Pipeline Programs↗

6

Active Trials↗

5

Companies Involved↗

Hepatocellular Cancer is an early-stage landscape with 4 programs across 5 companies. The most active players are AstraZeneca, Eli Lilly, OncoMed Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

63/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 2Eli Lilly logo

Eli Lilly

0 programs

PreclinicalO

OncoMed Pharmaceuticals, Inc.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalAmgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Monoclonal antibody

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSSmall molecule125%

Monoclonal antibody leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

30

clinical trials

Completed12 · 40%
Unknown status5 · 17%
Terminated4 · 13%
Withdrawn3 · 10%
Not yet recruiting3 · 10%
Recruiting2 · 7%
Other1 · 3%

Clinical Trials

Trial Activity

30 trials

Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
Recruiting·ZZhongshan People's Hospital, Guangdong, China·N/A·NCT07010198·4,500 enrolled
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT06363006·40 enrolled
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03937830·27 enrolled
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Not yet recruiting·—·Phase 2·NCT07226063·16 enrolled
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Not yet recruiting·UUniversity of Hawaii·Phase 1·NCT07075120·15 enrolled
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06935175·53 enrolled
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Completed·—·Phase 2·NCT00717756·41 enrolled
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02240433·9 enrolled
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Completed·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT02069145·10 enrolled
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Completed·—·Phase 2·NCT00775073·33 enrolled
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00355238·137 enrolled
STA-9090 in Patients With Advanced Hepatocellular Cancer
Completed·MMassachusetts General Hospital·Phase 1·NCT01665937·16 enrolled
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT03037437·64 enrolled
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02292173·17 enrolled
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Completed·—·Phase 1·NCT00997022·14 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)